Terms: = Bone cancer AND NF2, ACN, 4771, ENSG00000186575, P35240, SCH, Merlin, BANF AND Treatment
44 results:
1. Gene-targeted therapy for neurofibromatosis and schwannomatosis: The path to clinical trials.
Staedtke V; Anstett K; Bedwell D; Giovannini M; Keeling K; Kesterson R; Kim Y; Korf B; Leier A; McManus ML; Sarnoff H; Vitte J; Walker JA; Plotkin SR; Wallis D
Clin Trials; 2024 Feb; 21(1):51-66. PubMed ID: 37937606
[TBL] [Abstract] [Full Text] [Related]
2. Approach to the Patient With a Suppressed TSH.
Praw SS; Brent GA
J Clin Endocrinol Metab; 2023 Jan; 108(2):472-482. PubMed ID: 36329632
[TBL] [Abstract] [Full Text] [Related]
3. CD44 Contributes to the Regulation of MDR1 Protein and Doxorubicin Chemoresistance in Osteosarcoma.
Gerardo-Ramírez M; Keggenhoff FL; Giam V; Becker D; Groth M; Hartmann N; Straub BK; Morrison H; Galle PR; Marquardt JU; Herrlich P; Hartmann M
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955749
[TBL] [Abstract] [Full Text] [Related]
4. schisandrin B suppresses osteosarcoma lung metastasis
Wang Y; Chen J; Huang Y; Yang S; Tan T; Wang N; Zhang J; Ye C; Wei M; Luo J; Luo X
Oncol Rep; 2022 Mar; 47(3):. PubMed ID: 35029287
[TBL] [Abstract] [Full Text] [Related]
5. Lysine Demethylase 6B Regulates Prostate cancer Cell Proliferation by Controlling c-MYC Expression.
Yıldırım-Buharalıoğlu G
Mol Pharmacol; 2022 Feb; 101(2):106-119. PubMed ID: 34862309
[TBL] [Abstract] [Full Text] [Related]
6. Skull Base Tumors: Neuropathology and Clinical Implications.
Bi WL; Santagata S
Neurosurgery; 2022 Mar; 90(3):243-261. PubMed ID: 34164689
[TBL] [Abstract] [Full Text] [Related]
7. Clinical characteristics and management differences for grade II and III spinal meningiomas.
Krauss WE; Yolcu YU; Alvi MA; Moinuddin FM; Goyal A; Clarke MJ; Marsh WR; Bydon M
J Neurooncol; 2021 Jun; 153(2):313-320. PubMed ID: 33973145
[TBL] [Abstract] [Full Text] [Related]
8. [Management of patients developing acute gastro-intestinal graft-versus-host-disease: Guidelines from the Francophone Society of bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
de Berranger E; Charbonnier A; Davy E; Dendonker C; Denis V; Desmier D; Farrugia C; Guenounou S; Guilbert Y; Jost E; L'hostette A; Rialland F; Taque S; Yafour N; Seguy D; Yakoub Agha I
Bull Cancer; 2021 Dec; 108(12S):S30-S38. PubMed ID: 33966887
[TBL] [Abstract] [Full Text] [Related]
9. KLF4
von Spreckelsen N; Waldt N; Poetschke R; Kesseler C; Dohmen H; Jiao HK; Nemeth A; Schob S; Scherlach C; Sandalcioglu IE; Deckert M; Angenstein F; Krischek B; Stavrinou P; Timmer M; Remke M; Kirches E; Goldbrunner R; Chiocca EA; Huettelmaier S; Acker T; Mawrin C
Acta Neuropathol Commun; 2020 Apr; 8(1):41. PubMed ID: 32245394
[TBL] [Abstract] [Full Text] [Related]
10. Current treatment options for meningioma.
Apra C; Peyre M; Kalamarides M
Expert Rev Neurother; 2018 Mar; 18(3):241-249. PubMed ID: 29338455
[TBL] [Abstract] [Full Text] [Related]
11. Voxel-based lesion mapping of meningioma: a comprehensive lesion location mapping of 260 lesions.
Hirayama R; Kinoshita M; Arita H; Kagawa N; Kishima H; Hashimoto N; Fujimoto Y; Yoshimine T
J Neurosurg; 2018 Jun; 128(6):1707-1712. PubMed ID: 28862550
[TBL] [Abstract] [Full Text] [Related]
12. Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
Yesilöz Ü; Kirches E; Hartmann C; Scholz J; Kropf S; Sahm F; Nakamura M; Mawrin C
Neuro Oncol; 2017 Aug; 19(8):1088-1096. PubMed ID: 28482067
[TBL] [Abstract] [Full Text] [Related]
13. The effect and mechanism of dopamine D1 receptors on the proliferation of osteosarcoma cells.
Gao J; Zhang C; Gao F; Li H
Mol Cell Biochem; 2017 Jun; 430(1-2):31-36. PubMed ID: 28181134
[TBL] [Abstract] [Full Text] [Related]
14. A phase II study of clinical activity of sch 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma.
Anderson PM; Bielack SS; Gorlick RG; Skubitz K; Daw NC; Herzog CE; Monge OR; Lassaletta A; Boldrini E; Pápai Z; Rubino J; Pathiraja K; Hille DA; Ayers M; Yao SL; Nebozhyn M; Lu B; Mauro D
Pediatr Blood Cancer; 2016 Oct; 63(10):1761-70. PubMed ID: 27362300
[TBL] [Abstract] [Full Text] [Related]
15. Management of spinal tumors in neurofibromatosis type 2 patients.
Nowak A; Dziedzic T; Czernicki T; Kunert P; Marchel A
Neurol Neurochir Pol; 2016; 50(1):31-5. PubMed ID: 26851687
[TBL] [Abstract] [Full Text] [Related]
16. Clinical course and management of intracranial meningiomas in neurofibromatosis type 2 patients.
Nowak A; Dziedzic T; Czernicki T; Kunert P; Marchel A
Neurol Neurochir Pol; 2015; 49(6):367-72. PubMed ID: 26652870
[TBL] [Abstract] [Full Text] [Related]
17. Uncommon histiocytic disorders: Rosai-Dorfman, juvenile xanthogranuloma, and Erdheim-Chester disease.
Haroche J; Abla O
Hematology Am Soc Hematol Educ Program; 2015; 2015():571-8. PubMed ID: 26637774
[TBL] [Abstract] [Full Text] [Related]
18. Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.
Subbiah V; Wagner MJ; McGuire MF; Sarwari NM; Devarajan E; Lewis VO; Westin S; Kato S; Brown RE; Anderson P
Oncotarget; 2015 Dec; 6(38):40642-54. PubMed ID: 26510912
[TBL] [Abstract] [Full Text] [Related]
19. Genomic characterisation of two cancers of unknown primary cases supports a kidney cancer origin.
Wei EY; Chen YB; Hsieh JJ
BMJ Case Rep; 2015 Oct; 2015():. PubMed ID: 26494726
[TBL] [Abstract] [Full Text] [Related]
20. Clinical features of spinal schwannomas in 65 patients with schwannomatosis compared with 831 with solitary schwannomas and 102 with neurofibromatosis Type 2: a retrospective study at a single institution.
Li P; Zhao F; Zhang J; Wang Z; Wang X; Wang B; Yang Z; Yang J; Gao Z; Liu P
J Neurosurg Spine; 2016 Jan; 24(1):145-54. PubMed ID: 26407091
[TBL] [Abstract] [Full Text] [Related]
[Next]
